Head-to-head evidence
Gosogliptin vs Yogliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Gosogliptin
Developed by SatRx
NCT03088670 · Phase 3 · completed
The study used randomization and an active comparator, but it was open-label and its primary endpoint was change in HbA1c, a surrogate measure rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Yogliptin
Developed by Chengdu Easton Biopharmaceuticals
NCT05318326 · Phase 3 · status unknown
The trial randomly assigns patients to Yogliptin or a matching placebo and blinds patients, care providers, investigators and outcome assessors alike, using HbA1c change, the standard regulator-accepted measure for diabetes drugs, as its main result. Results have not been posted yet, so whether Yogliptin lowered blood sugar significantly more than placebo is not yet known.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gosogliptin's landscape · Yogliptin's landscape